 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12340/13424 (92%)
Visitors : 1973837
Online Users : 168
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/16491
|
| Title: | Advancing precision therapy for colorectal cancer: Developing clinical indications for multi-target kinase inhibitor BPR1J481 using patient-derived xenograft models |
| Authors: | Tang, YC;Ou, JJ;Hsu, SC;Huang, CH;Lin, LM;Chang, HH;Wang, YH;Huang, ZT;Sun, M;Liu, KJ;Hung, YM;Lai, CY;Shih, C;Chen, CT;Chang, JY;Hsieh, HP;Jiaang, WT;Kuo, CC |
| Contributors: | Institute of Biotechnology and Pharmaceutical Research;National Institute of Infectious Diseases and Vaccinology;National Institute of Cancer Research;Pathology Core Laboratory |
| Abstract: | The large and rapid increase in the incidence and mortality of colorectal cancer (CRC) demonstrates the urgent need for new drugs with higher efficacy to treat CRC. However, the lack of applicable and reliable preclinical models significantly hinders the progress of drug development. Patient-derived xenograft (PDX) models are currently considered reliable in vivo preclinical models for predicting drug efficacy in cancer patients. This study successfully uses the CRC PDX model to develop clinical indications for the new multi-target kinase inhibitor BPR1J481 and demonstrated the anti-cancer mechanism and competitive advantages of this drug candidate. The results demonstrate that BPR1J481 exhibits significant anticancer efficacy by inducing apoptosis in CRC PDX tumor tissues and corresponding PDX-derived CRC cells. Through kinase competitive binding and kinase activity assays, we discover that BPR1J481 effectively inhibits SRC kinase activity by directly binding to its active site. The reduction in SRC phosphorylation observed in CRC PDX tumor tissues and derived cells upon treatment with BPR1J481 further validates its inhibitory potential. Furthermore, the decrease in viable cells after SRC knockout and the poorer prognosis observed in patients with higher SRC expression, emphasizes the critical significance and clinical relevance of SRC in CRC. Additionally, BPR1J481 exhibits robust anti-angiogenic effects by suppressing VEGF- and PDGF-induced endothelial cell proliferation, migration, and capillary-like tube formation through inhibition of VEGFR2 and PDGFRβ phosphorylation. Remarkably, BPR1J481 appears to demonstrate greater efficacy against CRC compared to regorafenib. These findings highlight the therapeutic potential of BPR1J481 for patients with CRC. |
| Date: | 2025-01 |
| Relation: | Pharmacological Research. 2025 Jan;211:Article number 107556. |
| Link to: | http://dx.doi.org/10.1016/j.phrs.2024.107556 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:001394444600001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85212854255 |
| Appears in Collections: | [郭靜娟] 期刊論文
[蔣維棠] 期刊論文
[謝興邦] 期刊論文
[張俊彥] 期刊論文
[陳炯東] 期刊論文
[石全(2014-2017)] 期刊論文
[許素菁] 期刊論文
[劉柯俊] 期刊論文
[其他] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| SCP85212854255.pdf | | 10796Kb | Adobe PDF | 23 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
